Major Depressive Disorder Model Draft Protocol: Public Comment Period Presentation
Wednesday, December 15, 2021
IVI launched the Major Depressive Disorder (MDD) initiative to build a flexible, open-source, and patient-centric model that will help inform the decision needs of multiple stakeholders in the health care system.
According to the National Alliance on Mental Illness, over 19 million adults had at least one MDD episode in the past year; the COVID-19 pandemic has only exacerbated the unmet need for depression treatment. Conventional cost-effectiveness models for assessing the value of MDD treatments typically do not prioritize factors and outcomes important to patients.
This webinar covered the major points of the new model scope for the MDD initiative, and addressed the importance of a patient-centric model for MDD. Via a public comment period from April 12th to May 14th, stakeholders were invited to provide recommendations on the most important factors to build into the model.
Rick Chapman, PhD
Innovation and Value Initiative
Chief Science Officer for IVI. Prior to IVI, he was Director of Health Economics at ICER, where he led development of economic evaluations that accompanied reviews of clinical evidence, assessing the potential costs, cost-effectiveness, and budgetary impact of a wide range of pharmaceutical and other clinical interventions.
Jordana Schmier
OPEN Health
Ms. Schmier has been working in the health economics and outcomes field for 25 years. Her analyses of patient-reported outcomes and costs of pharmaceuticals, devices, and other health interventions have been widely published and used to support access, regulatory, and reimbursement decisions.
Richard Xie, PhD
Innovation and Value Initiative
A health economist and HEOR Manager at the Innovation and Value Initiative, Dr. Xie has played a lead role in developing the IVI-Major Depressive Disorder Model Scope. He has a long track record of conducting HEOR studies to inform health policy design and valuation of pharmaceutical therapies.